James Edgemond Sells 8,750 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 8,750 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $538.15, for a total value of $4,708,812.50. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,158,119.40. This represents a 31.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

James Edgemond also recently made the following trade(s):

• On Thursday, June 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $540.15, for a total value of $5,401,500.00.
• On Monday, June 15th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.17, for a total value of $5,491,700.00.
• On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.29, for a total value of $5,492,900.00.
• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.50, for a total value of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00.

United Therapeutics Price Performance

Shares of UTHR opened at $549.66 on Thursday. The company has a market capitalization of $23.33 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company’s fifty day moving average price is $562.63 and its 200 day moving average price is $525.08.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company earned $6.63 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Arjuna Capital boosted its position in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares in the last quarter. Clearstead Advisors LLC lifted its stake in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares during the period. Sage Rhino Capital LLC grew its stake in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC boosted its stake in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its position in United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 26 shares during the period. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Bank of America upped their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.